NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue:
Growth Factors (Blood And Tissue) - A World Report
Advertisement
http://www.reportlinker.com/p0164229/Growth-Factors-Blood-And-Tissue---A-World-Report.html
Age-related conditions such as Alzheimer's disease, malignancies, trauma and autoimmune disorders necessitate the development of less-invasive and more effective therapies. Growth factors (blood and tissue) have made an indelible mark on the market as a promising and cost-effective therapeutic solution for addressing unmet medical needs. Growth factors have a wide range of opportunities, especially in treating critical conditions such as granulocytopenia, leukemia, aplastic anaemia, bone marrow transplantation, and myelodysplastic syndrome. Additionally, human recombinant technologies have triggered these therapeutic biological products to greater heights.
Advertisement
These and other market data and trends are presented in "Growth Factors ( Blood And Tissue ): A World Report" by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.
GROWTH FACTORS (BLOOD AND TISSUE) BMR-1029
CONTENTS
1. METHODOLOGY 1
Study Reliability and Reporting Limitations 1
Disclaimers 2
Quantitative Techniques & Reporting Level 3
2. INTRODUCTION 4
Growth Factors: A Preface 4
Growth Factors: Their Role and Related Applications 4
Growth Factors: Adding a New Dimension 4
Growth Factors: Classification Based on Activity 4
Recent Trends & Developments 5
Recombinant Human Erythropoietin: Gradually Gaining Dominance 5
3. MARKET OVERVIEW 5
EPO - The Lead 'Factor' 5
Leading EPO Drugs Worldwide 6
Market Comparison of Erythropoietin-Based Drugs in America
and European Union: Classification Based on Key Parameters 6
Patent Expiries of Major Biopharmaceutical Drugs 7
4. MARKET DYNAMICS 7
Dethroning the Leaders 7
Expiration of Patents Fuels Competition and Sales 8
India - At the Center Stage 8
Side Effects - Still a Concern 8
CDER- A Regulatory Review Authority for Growth Factors 9
5. OUTLOOK 9
Innovative Delivery System Shows Potential for Accelerating
Use of Growth Factors 9
Cytokines - Vital Growth Propellers for the Future of New Drugs 9
Brain Derived Neurotrophic Factor (BDNF) Finds Increased
Application 10
Age-Related Diseases - Their Influence on Effective Therapies 10
Copaxone Finds Novel Applications 10
Mimetic Growth Factors - Exhibiting Promising Potential 11
6. INDUSTRY ISSUES 11
Development of Cost Effective Methods - Need of the Hour 11
Influence of Neurotrophic Factors on Brain Cell Development 12
Combination of Interferons and Ribavirin Develops More Anemia
Cases 12
7. COMPETITIVE TRENDS 13
RegeneRx Focuses on Wound Healing Market 13
DRL Introduces a Program to Propel its Biogenerics Business 13
8. PRODUCT FACTS 13
Blood Growth Factors 14
Erythropoietins 14
Colony Stimulating Factors 14
Interferons 14
Types of Interferons 14
Interleukins 15
Types of Interleukins 15
Tissue Growth Factors 16
Tissue Growth Factors: Classification Based on Key Source and
Principal Activity 16
Growth Factors: Application by Compound and Supplier 17
Growth Factors: Indicated Applications by Site/Course of Action 18
9. RESEARCH AND DEVELOPMENT HIGHLIGHTS 18
Maxygen Updates on Factor VII Program 18
Evaluation of Extended Dosing Schedule of PROCRIT® 19
PROCRIT® - A Better Option 19
Nerve Growth Factor Shows Promising Potential Against Diabetes 19
Cytokines and GM-CSF Found to be Closely Interlinked 20
GM-CSF Enhances Rate of Survival in Neonates 20
rG-CSF Well Tolerated in Pneumonia and Severe Sepsis Patients 20
rG-CSF- Their Influence on Preterm Infants with Sepsis 21
Serum Macrophage Colony Stimulating Growth Factors Associated
with Thrombocyte and Monocyte 21
Src Pathway Inactivation in Kit Impairs Blood Cell Growth and
Proliferation 22
Cole Eye Institute Offers TIMP-3 Mechanism for Preventing
Abnormal Growth of Blood Vessels 22
Effect of Brain Derived Neurotrophic Factor on Retinal Cells 23
Orcel(TM) Exhibits High Growth Factor for Wound Healing and
Cardiovascular Applications 23
Drug Combination of Macrophage Colony Stimulating Factor Shows
Successful Tolerance Levels 23
Neotrofin(TM) Triggers Neurotrophic Factors 24
G-CSF Shows Capability for Promoting Neutrophil Production 24
Insulin-like Growth Factor-1 (IGF) Gene Transfer Accelerates
Wound Healing Process 25
Hepatocyte Growth Factors - Exhibiting Dual Role 25
Cortex Pharmaceuticals Ampakines® Promotes Expression of
Neurotrophin 25
Granulocyte Colony Stimulating Factor Finds Application in
Treating Neonates 26
Cerebrolysin Promotes Cognition 26
10. BREAKTHROUGHS - A REVIEW 26
Novel Set of Human Cytokines Unveiled 26
IGFBP-3 and its Potential to Ward Off Gastric Cancer 27
Bone Morphogenic Proteins Show Potential for Musculoskeletal
Regeneration 27
Growth Factors - Their Role in Preventing Heart Stroke 27
Growth Factor Proteins Shows Promising Results for Treating
Cancer 27
Neurotrophic Growth Factor Primarily Responsible for Loss of
Vision 27
Redox-Active Grape Seed Exhibits Favorable Properties for
Dermal Wound Healing 28
Role of Brain-Derived Neurotrophic Factor on Memory 28
Nerve Growth Factor Found to Enhance Barium Current and
Insulin Secretion 28
Lipid Peroxidation May be Associated with Wound Healing 29
Genentech Inc Unveils Molecule for Stimulating Growth of Blood
Vessels 29
Connective Tissue Growth Factor Found to Promote Lung Fibroblast 29
Influence of Insulin-Like Growth Factor on Growth 30
Regeneron Discovers Angiopoietins Targeted at Blood Vessel
Growth and Repair 30
Environment and Insulin-Like Growth Factors Stimulate Risk of
Cancer 30
Cocktail of Neurotrophic Factors Promotes Regeneration of Torn
Nerves 31
Growth Factors Administration to Stimulate Tissue Repair 31
Cytokine - Their Role in Combating Hepatitis C Virus 31
Axokine® Yields Favorable Results Against Obesity 31
Cell Genesys Unveils GDNF Gene Therapy Targeted Against
Parkinson's Disease 32
11. CORPORATE DEVELOPMENTS 32
Pfizer Inks Exclusive Global Licensing Agreement with Scil
Technology 32
ZGEN Initiates Ph II Trial of Interleukin 21 32
FzioMed Bags Health Canada Approval on Oxiplex® 33
NsGene A/S Implants Encapsulated Cell in Patients 33
Reliance Life Sciences Takes Over Genemedix 33
Fraunhofer Institute Introduces First Interferon Beta 1a to
Treat Multiple Sclerosis 33
Shanghai Wanxing Inks Export Deal for Recombinant Human
Interferon 34
Hemispherx Enters into Distribution Agreement with Armada 34
Bayer Launches US Pharmaceuticals Subsidiary 34
Merck Inks Agreement with Bristol-Myers Squibb and ImClone 35
CoGenesys Signs Global Licensing Agreement with Vegenics 35
InterMune Inks New Supply Deal with Boehringer Ingelheim 35
Boston Life Sciences Adopts New Name of Alseres Pharmaceuticals 36
Cambrex Divests Bioproducts and Biopharma Subsidiaries 36
Dragon Divests EPO Business 36
Caregene and Genzyme Forms Partnership to Develop Cere-120 37
Amgen Bags EC Approval on Use of Aranesp(R) in Paediatric
Patients 37
NsGene to Undertake Phase Ib Clinical Trial of NsG0202 37
Roche Receives European Approval for NeoRecormon 38
Bolder Receives Two U.S. Patents for Hematopoietic Factors 38
Hospira Receives EC Approval on Retacrit 38
RLS to Initiate Clinical Trials of Erythropoietin 38
InterMune Drops Phase III trial of Interferon 38
Chugai to Conduct Additional Trial on Epogin® 39
12. MAJOR PLAYERS 39
Amgen, Inc. (USA) 39
BioMimetic Therapeutics, Inc. (USA) 39
Biopharm GmbH (Germany) 39
Bolder Biotechnology, Inc. (USA) 39
Alseres Pharmaceuticals, Inc. (USA) 40
Ceregene, Inc. (USA) 40
FibroGen, Inc. (USA) 40
FzioMed, Inc. (USA) 40
Insmed, Inc. (USA) 41
Johnson & Johnson (USA) 41
Janssen-Ortho, Inc. (Canada) 41
Lonza Group (Switzerland) 42
Maxygen, Inc. (USA) 42
Merck Serono International S.A. (Switzerland) 42
NsGene A/S (Denmark) 42
PeproTech, Inc. (USA) 43
Rentschler Biotechnologie GmbH (Germany) 43
F. Hoffmann-La Roche Ltd (Switzerland) 43
Chugai Pharmaceutical Co. Ltd. (Japan) 43
Genentech, Inc. (USA) 44
Shantha Biotechnics (India) 44
Scil Proteins GmbH (Germany) 44
Wockhardt Ltd. (India) 44
13. MARKET ANALYTICS 45
14. THE UNITED STATES 53
EPO Market Scenario 53
Key Market Driver for EPO 53
Leading EPO Drugs in the US 53
15. JAPAN 55
Erythropoietin Market: Competitive Scenario 55
Leading EPO Drugs in Japan 55
Market Scenario for Biotech Products 55
Biotech Market Backed by Public Assistance 55
16. EUROPE 57
17. REST OF WORLD 58
An Overview of Indian Market 58
Erythropoietin 58
G-CSF Market 59
Interferon 59
EXHIBITS
Table 1: Global Growth Factors (Blood and Tissue) Market by
Region for the Period 2007-2015 (Sales in US$ Million)
Table 2: Percentage Breakdown of Global Growth Factors (Blood
and Tissue) Market by Region for the Years 2008 & 2012
Table 3: Global Blood Growth Factors Market by Region for the
Period 2007-2015 (Sales in US$ Million)
Table 4: Percentage Breakdown of Global Blood Growth Factors
Market by Region for the Years 2008 & 2012
Table 5: Global Blood Growth Factors Market by Type for the
Period 2007-2015 (Sales in US$ Million)
Table 6: Percentage Breakdown of Global Blood Growth Factors
Market by Type for the Years 2008 & 2012
Table 7: Global Erythropoietins Market by Region for the
Period 2007-2015 (Sales in US$ Million)
Table 8: Percentage Breakdown of Global Erythropoietins Market
by Region for the Years 2008 & 2012
Table 9: Global Colony Stimulating Factors Market by Region
for the Period 2007-2015 (Sales in US$ Million)
Table 10: Percentage Breakdown of Global Colony Stimulating
Factors Market by Region for the Years 2008 & 2012
Table 11: Global Interferons Market by Region for the Period
2007-2015 (Sales in US$ Million)
Table 12: Percentage Breakdown of Global Interferons Market by
Region for the Years 2008 & 2012
Table 13: Global Interleukins Market by Region for the Period
2007-2015 (Sales in US$ Million)
Table 14: Percentage Breakdown of Global Interleukins Market
by Region for the Years 2008 & 2012
Table 15: Global Tissue Growth Factors Market by Region for
the Period 2007-2015 (Sales in US$ Million)
Table 16: Percentage Breakdown of Global Tissue Growth Factors
Market by Region for the Years 2008 & 2012
Table 17: Growth Factors (Blood and Tissue) Market by Type in
the US: 2007-2015 (Sales in US$ Million)
Table 18: Percentage Breakdown of Growth Factors (Blood and
Tissue) Market by Type in the US for the Years 2008 & 2012
Table 19: Growth Factors (Blood and Tissue) Market by Type in
Japan: 2007-2015 (Sales in US$ Million)
Table 20: Percentage Breakdown of Growth Factors (Blood and
Tissue) Market by Type in Japan for the Years 2008 & 2012
Table 21: Growth Factors (Blood and Tissue) Market by Type in
Europe: 2007-2015 (Sales in US$ Million)
Table 22: Percentage Breakdown of Growth Factors (Blood and
Tissue) Market by Type in Europe for the Years 2008 & 2012
Table 23: Growth Factors (Blood and Tissue) Market by Type in
the Rest of World: 2007-2015 (Sales in US$ Million)
Table 24: Percentage Breakdown of Growth Factors (Blood and
Tissue) Market by Type in the Rest of World for the Years 2008
& 2012
COMPANIES PROFILED
To order this report:
Diagnostics Industry: Growth Factors (Blood And Tissue) - A World Report
More Market Research Report
Contact:Nicolas BombourgReportlinkerEmail: [email protected]: (805)652-2626Intl: +1 805-652-2626
SOURCE Reportlinker
